How Much Weight Do Lilly's Obesity Drugs Help People
Quick Facts
What do clinical trials show about tirzepatide and weight loss?
Tirzepatide, a dual GIP and GLP-1 receptor agonist marketed as Zepbound and Mounjaro, was studied in the SURMOUNT-1 trial published in the New England Journal of Medicine in 2022 by Jastreboff and colleagues. Average weight reduction was about 15% at 5 mg and about 20.9% at 15 mg over 72 weeks, versus roughly 3% with placebo.
These are averages. Individual responses vary widely, and some participants lost far more or far less. Weight loss is usually measured as percentage change in body weight, and results can differ between people with and without type 2 diabetes, who generally lose somewhat less.
What about Lilly's newer candidates such as orforglipron and retatrutide?
Orforglipron is a small-molecule oral GLP-1 receptor agonist that does not require injection or food restrictions. In the ATTAIN-1 trial, reported in the New England Journal of Medicine in 2025, the highest dose produced average weight loss of about 12% at 72 weeks. Retatrutide, which targets GIP, GLP-1 and glucagon receptors, showed up to roughly 24% average weight loss at 48 weeks in a phase 2 study published in the same journal in 2023.
Phase 3 programs and regulatory reviews determine how these drugs will be used. Safety findings so far are mainly gastrointestinal, including nausea, vomiting, diarrhea and constipation, typically most pronounced during dose escalation.
How should patients interpret headline weight-loss numbers?
Trial participants receive lifestyle counseling and close monitoring, which may not match real-world care. Average results also hide a range of outcomes, and discontinuation commonly leads to weight regain.
Patients should discuss eligibility, expected benefit, other health conditions and long-term plans with a clinician. Medication is one tool within a broader approach to nutrition, activity and chronic disease management.
Frequently Asked Questions
Average loss was about 15% to 21% of body weight over 72 weeks depending on dose, compared with roughly 3% for placebo.
It is an investigational oral, once-daily GLP-1 receptor agonist from Eli Lilly that has shown weight loss in phase 3 trials.
Gastrointestinal symptoms such as nausea, vomiting, diarrhea and constipation are most common, especially while the dose is being increased.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023.
- Reuters. Lilly says its obesity drugs helped patients lose weight in clinical trials. 2026.